Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiation Priming of Immunotherapy in NSCLC and HNSCC
NCT03313804Phase 2Completed
- Start
- Oct 2017
- Primary completion
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, pembrolizumab, atezolizumab in non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (HNSCC). Started Oct 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03313804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03313804.